Anika Enrolls First Patient in Monovisc Study
Posted on: Tuesday, 8 January 2008, 03:00 CST
Anika Therapeutics has enrolled the first patient in a multi-center, randomized, double-blind, controlled study evaluating its single-injection osteoarthritis product, Monovisc.
The study is designed to demonstrate that the single-injection Monovisc safely provides symptomatic relief of knee pain and associated dysfunction in patients with osteoarthritis. Anika plans to enroll approximately 350 patients at up to 20 sites in the US and Canada.
Charles Sherwood, Anika's president and CEO, said: "The initiation of this study is a key step toward commercialization of our Monovisc product in the US. Monovisc leverages our new technology platform using a cross-linked, non-animal source of hyaluronic acid, delivered in an easy-to-use, single injection format. Administering this solution through a single injection can offer a convenient option for doctors and patients."
Source: Datamonitor
Related Articles
- FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
- Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
- Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
- The Medicines Company Supports Landmark Patient Observational Study and Clinical Survey on Acute Severe Hypertension
- SinoFresh Reports Patient Case Study: Allergic Fungal Rhinosinusitis in Adult Male With History of Sinus Conditions
- VELCADE(R) (Bortezomib) for Injection Single-Agent and Combination Studies Show Positive Outcomes in a Broad Range of Multiple Myeloma Patients
- Atherogenic Lipid Profile and Cardiovascular Risk Factors in HIV- Infected Patients (Ntar Study)
- Genentech Stops Enrolling Patients in Study
- Phase 2 Study Shows Lilly/Alkermes Inhaled Insulin System Achieved Blood Sugar Levels Similar to Injected Insulin; 80 Percent of Diabetes Patients in Study Preferred Inhaled Insulin System to Mealtime Injections
- Two New Studies in the British Journal of Haematology Show Potential Role of VELCADE(R) (Bortezomib) for Injection in Treating Patients With Front-Line Multiple Myeloma
 |
 |
User Comments (0)
RSS Feeds